John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 3,604 shares at $7.61 ($27K) on 2022-03-18, disclosed to the SEC on 2022-03-21.
Scheduled sale ($27k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.51 | 900 | $7K | 24.9% |
| 2 | $7.61 | 1,204 | $9K | 33.8% |
| 3 | $7.47 | 1,500 | $11K | 41.3% |
| Total | $7.53 avg | 3,604 | $27K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |